Oncology-focused Beta Drugs raises Rs 117 crore from Healthquad, others

Beta Drugs connected Wednesday announced Healthquad Fund II, a Singapore-based concern money and a backstage wealthiness absorption firm, has picked up a number involvement successful the oncology-focused formulations institution by investing Rs 117 crore.

The institution volition usage the recently raised funds to accelerate its maturation and aspires to beryllium among the apical 5 oncology companies successful India implicit the adjacent 5 years, its president and managing manager Rahul Batra said.

In the statement, the institution claimed that it is 1 of the fastest-growing oncology formulation companies successful the country, with offerings similar chemotherapy, targeted, hormonal and supportive therapy for crab patients.  The institution sells its products successful 46 countries.

Ajay Mahipal, a spouse a Healthquad, -- which backs businesses seeking to amended healthcare access, affordability, and prime of attraction -- said with its beardown manufacturing and probe and improvement capabilities, Beta is poised to amended affordability successful the middle- and lower-income segment, and accessibility successful tier II and tier III cities successful the country.